143 related articles for article (PubMed ID: 15081035)
1. Bioisosteric replacement of anilide with benzoxazole: potent and orally bioavailable antagonists of VLA-4.
Lin LS; Lanza TJ; Castonguay LA; Kamenecka T; McCauley E; Van Riper G; Egger LA; Mumford RA; Tong X; MacCoss M; Schmidt JA; Hagmann WK
Bioorg Med Chem Lett; 2004 May; 14(9):2331-4. PubMed ID: 15081035
[TBL] [Abstract][Full Text] [Related]
2. A novel and potent VLA-4 antagonist based on trans-4-substituted cyclohexanecarboxylic acid.
Muro F; Iimura S; Yoneda Y; Chiba J; Watanabe T; Setoguchi M; Takayama G; Yokoyama M; Takashi T; Nakayama A; Machinaga N
Bioorg Med Chem; 2009 Feb; 17(3):1232-43. PubMed ID: 19124247
[TBL] [Abstract][Full Text] [Related]
3. Pyridone derivatives as potent, orally bioavailable VLA-4 integrin antagonists.
Witherington J; Blaney EL; Bordas V; Elliott RL; Gaiba A; Garton N; Green PM; Naylor A; Smith DG; Spalding DJ; Takle AK; Ward RW
Bioorg Med Chem Lett; 2006 Nov; 16(21):5538-41. PubMed ID: 16931004
[TBL] [Abstract][Full Text] [Related]
4. Discovery of a potent, orally bioavailable pyrimidine VLA-4 antagonist effective in a sheep asthma model.
Semko CM; Chen L; Dressen DB; Dreyer ML; Dunn W; Farouz FS; Freedman SB; Holsztynska EJ; Jefferies M; Konradi AW; Liao A; Lugar J; Mutter L; Pleiss MA; Quinn KP; Thompson T; Thorsett ED; Vandevert C; Xu YZ; Yednock TA
Bioorg Med Chem Lett; 2011 Mar; 21(6):1741-3. PubMed ID: 21316228
[TBL] [Abstract][Full Text] [Related]
5. Influence of acid surrogates toward potency of VLA-4 antagonist.
Venkatraman S; Lim J; Cramer M; Gardner MF; James J; Alves K; Lingham RB; Mumford RA; Munoz B
Bioorg Med Chem Lett; 2005 Sep; 15(18):4053-6. PubMed ID: 16039122
[TBL] [Abstract][Full Text] [Related]
6. Discovery of potential integrin VLA-4 antagonists using pharmacophore modeling, virtual screening and molecular docking studies.
Thangapandian S; John S; Sakkiah S; Lee KW
Chem Biol Drug Des; 2011 Aug; 78(2):289-300. PubMed ID: 21507205
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis, and biological evaluation of novel potent and selective alphavbeta3/alphavbeta5 integrin dual inhibitors with improved bioavailability. Selection of the molecular core.
Marugán JJ; Manthey C; Anaclerio B; Lafrance L; Lu T; Markotan T; Leonard KA; Crysler C; Eisennagel S; Dasgupta M; Tomczuk B
J Med Chem; 2005 Feb; 48(4):926-34. PubMed ID: 15715463
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and biological evaluation of benzoic acid derivatives as potent, orally active VLA-4 antagonists.
Chiba J; Iimura S; Yoneda Y; Watanabe T; Muro F; Tsubokawa M; Iigou Y; Satoh A; Takayama G; Yokoyama M; Takashi T; Nakayama A; Machinaga N
Bioorg Med Chem; 2007 Feb; 15(4):1679-93. PubMed ID: 17194595
[TBL] [Abstract][Full Text] [Related]
9. Discovery of N-{N-[(3-cyanobenzene) sulfonyl]-4(R)-(3,3-difluoropiperidin-1-yl)-(l)-prolyl}-4-[(3',5'-dichloro-isonicotinoyl) amino]-(l)-phenylalanine (MK-0617), a highly potent and orally active VLA-4 antagonist.
Venkatraman S; Lebsack AD; Alves K; Gardner MF; James J; Lingham RB; Maniar S; Mumford RA; Si Q; Stock N; Treonze KM; Wang B; Zunic J; Munoz B
Bioorg Med Chem Lett; 2009 Oct; 19(19):5803-6. PubMed ID: 19713111
[TBL] [Abstract][Full Text] [Related]
10. Amidines as amide bond replacements in VLA-4 antagonists.
Kamenecka TM; Park YJ; Lin LS; de Laszlo S; McCauley ED; Van Riper G; Egger L; Kidambi U; Mumford RA; Tong S; Tang W; Colletti A; Teffera Y; Stearns R; MacCoss M; Schmidt JA; Hagmann WK
Bioorg Med Chem Lett; 2004 May; 14(9):2323-6. PubMed ID: 15081033
[TBL] [Abstract][Full Text] [Related]
11. Constraining the amide bond in N-sulfonylated dipeptide VLA-4 antagonists.
Chang LL; Yang GX; McCauley E; Mumford RA; Schmidt JA; Hagmann WK
Bioorg Med Chem Lett; 2008 Mar; 18(5):1688-91. PubMed ID: 18242984
[TBL] [Abstract][Full Text] [Related]
12. The discovery of acylated beta-amino acids as potent and orally bioavailable VLA-4 antagonists.
Lin LS; Kopka IE; Mumford RA; Magriotis PA; Lanza T; Durette PL; Kamenecka T; Young DN; de Laszlo SE; McCauley E; Riper GV; Kidambi U; Egger LA; Tong X; Lyons K; Vincent S; Stearns R; Colletti A; Teffera Y; Fenyk-Melody J; Schmidt JA; MacCoss M; Hagmann WK
Bioorg Med Chem Lett; 2002 Feb; 12(4):611-4. PubMed ID: 11844683
[TBL] [Abstract][Full Text] [Related]
13. Pyridone derivatives as potent and selective VLA-4 integrin antagonists.
Witherington J; Bordas V; Gaiba A; Green PM; Naylor A; Parr N; Smith DG; Takle AK; Ward RW
Bioorg Med Chem Lett; 2006 Apr; 16(8):2256-9. PubMed ID: 16455247
[TBL] [Abstract][Full Text] [Related]
14. Identified a morpholinyl-4-piperidinylacetic acid derivative as a potent oral active VLA-4 antagonist.
Chiba J; Machinaga N; Takashi T; Ejima A; Takayama G; Yokoyama M; Nakayama A; Baldwin JJ; McDonald E; Moriarty KJ; Sarko CR; Saionz KW; Swanson R; Hussain Z; Wong A
Bioorg Med Chem Lett; 2005 Jan; 15(1):41-5. PubMed ID: 15582407
[TBL] [Abstract][Full Text] [Related]
15. 2,6-Quinolinyl derivatives as potent VLA-4 antagonists.
Lassoie MA; Broeders F; Collart P; Defrère L; de Laveleye-Defais F; Demaude T; Gassama A; Guillaumet G; Hayez JC; Kiss L; Knerr L; Nicolas JM; Norsikian S; Quéré L; Routier S; Verbois V; Provins L
Bioorg Med Chem Lett; 2007 Jan; 17(1):142-6. PubMed ID: 17035017
[TBL] [Abstract][Full Text] [Related]
16. Highly constrained bicyclic VLA-4 antagonists.
Chang LL; Truong Q; Doss GA; MacCoss M; Lyons K; McCauley E; Mumford R; Forrest G; Vincent S; Schmidt JA; Hagmann WK
Bioorg Med Chem Lett; 2007 Feb; 17(3):597-601. PubMed ID: 17118652
[TBL] [Abstract][Full Text] [Related]
17. Imidazopyridines as VLA-4 integrin antagonists.
Phillips DJ; Davenport RJ; Demaude TA; Galleway FP; Jones MW; Knerr L; Perry BG; Ratcliffe AJ
Bioorg Med Chem Lett; 2008 Jul; 18(14):4146-9. PubMed ID: 18539454
[TBL] [Abstract][Full Text] [Related]
18. Characterization of alpha(4)beta(1) (CD49d/CD29) on equine leukocytes: potential utility of a potent alpha(4)beta(1) (CD49d/CD29) receptor antagonist in the treatment of equine heaves (recurrent airway obstruction).
Treonze KM; Alves K; Fischer P; Hagmann WK; Hora D; Kulick A; Vakerich K; Smith ND; Lingham RB; Maniar S; Reger TS; Zunic J; Munoz B; Prasit P; Nicholson D; Si Q; Judd K; Nicolich S; Kellerhouse P; Thompson D; Mumford RA
Vet Immunol Immunopathol; 2009 Jul; 130(1-2):79-87. PubMed ID: 19250687
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and biological evaluation of novel pyridazinone-based alpha4 integrin receptor antagonists.
Gong Y; Barbay JK; Dyatkin AB; Miskowski TA; Kimball ES; Prouty SM; Fisher MC; Santulli RJ; Schneider CR; Wallace NH; Ballentine SA; Hageman WE; Masucci JA; Maryanoff BE; Damiano BP; Andrade-Gordon P; Hlasta DJ; Hornby PJ; He W
J Med Chem; 2006 Jun; 49(11):3402-11. PubMed ID: 16722660
[TBL] [Abstract][Full Text] [Related]
20. Synthesis, biological evaluation, and pharmacokinetic study of prolyl-1-piperazinylacetic acid and prolyl-4-piperidinylacetic acid derivatives as VLA-4 antagonists.
Chiba J; Takayama G; Takashi T; Yokoyama M; Nakayama A; Baldwin JJ; McDonald E; Moriarty KJ; Sarko CR; Saionz KW; Swanson R; Hussain Z; Wong A; Machinaga N
Bioorg Med Chem; 2006 Apr; 14(8):2725-46. PubMed ID: 16377201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
